Skip to main content

Advertisement

Fig. 3 | EJNMMI Research

Fig. 3

From: Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis

Fig. 3

Patient A. Pre- and post-18F-FDG PET/CT, lesion in the right lung with a significant decrease in TLuG and a significant increase in DLCOc (% predicted), while SUVmax increases. Patient A showed persistent extensive parenchymal and endobronchial involvement with an impaired diffusion capacity despite corticosteroid treatment. Infliximab was initiated, and after 6 months of treatment, diffusion capacity increased with 9.8%. Furthermore, TLuG decreased with 11.8%. However, in contrast to TLuG, the SUVmax increased with + 32.4%

Back to article page